CHO-MK: The Next Generation of Antibody Production? Dear Upstream Community, it is time for coffee & recent research about YFC (your favorite cells)! Today's publication highlights the use of a ...

MK-6070 is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition ...

Cancer patients may require COVID-19 vaccinations more often than the general public, but guidance is needed, researchers say ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Stem cell therapies are one of the most promising areas of medicine, and many such therapies are now in development by industrial and academic groups. Therapies based on adult stem cells have been ...

Inventia Life Science, an innovator in 3D cell culture technologies, announces the launch of RASTRUM™ Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug ...

Jan. 31, 2025 — Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defenders -- T cells -- lose their ability to ...

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of ...

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.